Search - tctmd.com

Displaying 1 - 20 of 20

Sort: Relevancy | Date

‘Promising’ SENTINEL Cerebral Protection in TAVR Collects Debris but Misses Primary Endpoint

News Conference News TCT 2016

Sentinel Cerebral Protection Device in TAVR ‘Promising’ but Trial Misses Primary Endpoint

Shelley Wood

November 01, 2016

Presentation TCT 2016

Rationale for and Design of SAPIEN LOW RISK and EVOLUTE LOW RISK

Presenter: Michael Argenziano, Alec S. Vahanian, Patrick T. O'Gara

October 31, 2016

Presentation TCT 2016

Low-Risk Studies: Design and Updates III - The Evolut R Low-Risk Trial

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Jeffrey J. Popma

October 30, 2016

News Daily News

At 3 Years Post-TAVR, Valve Performance Holds Steady and Most Mortality Is Noncardiac: FRANCE 2 Registry

Caitlin E. Cox

October 04, 2016

News Daily News

Sapien 3 Approved for Use in Intermediate-Risk Patients in Europe

Michael O'Riordan

September 20, 2016

News Daily News

Survival Better, No ‘Risk Creep’ for TAVR vs Surgery in Lower-Risk Patients

L.A. McKeown

August 24, 2016

News Daily News

FDA Approves Sapien XT and Sapien 3 for Intermediate-Risk Patients

Yael L. Maxwell

August 18, 2016

News Daily News

Next-Generation CoreValve Device Receives CE Mark for Use in Intermediate-Risk Patients

Todd Neale

August 01, 2016

News Daily News

Thrombus Relatively Common After LAA Occlusion With Amplatzer Amulet, Small Study Suggests

Todd Neale

July 28, 2016

News Conference News TVT 2016

Teenage TAVR: Should Practice Forge on While Guidelines Grow Up?

Michael O'Riordan

June 20, 2016

News Conference News TVT 2016

Not All Valves With Leaflet Thickening Develop Mobility Problems, Repeat 4D CT Shows in SAVORY

Michael O'Riordan

June 18, 2016

News Conference News TVT 2016

What TAVR Needs Next . . . and What It’s Getting

Shelley Wood

June 17, 2016

News Daily News

Equivalent Mortality at 30 Days and 1 Year With TAVR vs Surgery, Says Large Meta-analysis

Michael O'Riordan

June 07, 2016

News Conference News EuroPCR 2012

EuroPCR 2012: Biodegradable Devices, Imaging Take Center Stage

Caitlin E. Cox

May 22, 2012

News Daily News

Local Anesthesia Feasible, Safe in Transfemoral TAVR

May 11, 2012

News Conference News ACC 2012

ACC-i2 Scientific Session 2012: Cooperation Key as Practice Changing Results Released

Yael L. Maxwell

April 02, 2012

News Conference News ACC 2012

ADVANCE: TAVR with CoreValve Safe, Effective at 6 Months

March 24, 2012

News Daily News

Patient Selection Trends Younger, Less High Risk for Transcatheter Valve Therapy

March 06, 2012

News Daily News

CoreValve Appears a Feasible Replacement for Failed Surgical Aortic Valves

October 03, 2011

News Daily News

FDA Panel Recommends Approval of Transcatheter Heart Valve

July 21, 2011

Advertisement

Sentinel Cerebral Protection Device in TAVR ‘Promising’ but Trial Misses Primary Endpoint

Rationale for and Design of SAPIEN LOW RISK and EVOLUTE LOW RISK

Low-Risk Studies: Design and Updates III - The Evolut R Low-Risk Trial

At 3 Years Post-TAVR, Valve Performance Holds Steady and Most Mortality Is Noncardiac: FRANCE 2 Registry

Sapien 3 Approved for Use in Intermediate-Risk Patients in Europe

Survival Better, No ‘Risk Creep’ for TAVR vs Surgery in Lower-Risk Patients

FDA Approves Sapien XT and Sapien 3 for Intermediate-Risk Patients

Next-Generation CoreValve Device Receives CE Mark for Use in Intermediate-Risk Patients

Thrombus Relatively Common After LAA Occlusion With Amplatzer Amulet, Small Study Suggests

Teenage TAVR: Should Practice Forge on While Guidelines Grow Up?

Not All Valves With Leaflet Thickening Develop Mobility Problems, Repeat 4D CT Shows in SAVORY

What TAVR Needs Next . . . and What It’s Getting

Equivalent Mortality at 30 Days and 1 Year With TAVR vs Surgery, Says Large Meta-analysis

EuroPCR 2012: Biodegradable Devices, Imaging Take Center Stage

Local Anesthesia Feasible, Safe in Transfemoral TAVR

ACC-i2 Scientific Session 2012: Cooperation Key as Practice Changing Results Released

ADVANCE: TAVR with CoreValve Safe, Effective at 6 Months

Patient Selection Trends Younger, Less High Risk for Transcatheter Valve Therapy

CoreValve Appears a Feasible Replacement for Failed Surgical Aortic Valves

FDA Panel Recommends Approval of Transcatheter Heart Valve

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content